Basic Information
| LncRNA/CircRNA Name | GACAT3 |
| Synonyms | NA |
| Region | GRCh38_2:16050427-16085801 |
| Ensemble | ENSG00000236289 |
| Refseq | NR_126559 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | glioma tissues, U87 and U251 cell lines,normal human astrocyte (NHA) cell line |
| Expression Pattern | up-regulated |
| Function Description | GACAT3 is upregulated in glioma tissues and cell lines. Through online databases, luciferase reporter assays and RNA immunoprecipitation (RIP) assays, we determined that GACAT3 acts as a competing endogenous RNA (ceRNA) for microRNA (miR) 135a, which was downregulated and performed as a tumor inhibitor in glioma. Further, nicotinamide phosphoribosyl transferase (NAMPT) was confirmed as a target gene of miR 135a by a series of gain and loss of function assays. |
| Pubmed ID | 30536379 |
| Year | 2018 |
| Title | Long noncoding RNA GACAT3 promotes glioma progression by sponging miR-135a |
External Links
| Links for GACAT3 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |